XTANT MEDICAL HOLDINGS, INC. Financials Xtant Medical Holdings, Inc.
Equities
XTNT
US98420P3082
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6924 USD | -12.47% |
|
-14.52% | -38.73% |
| May. 15 | Earnings Flash (XTNT) XTANT MEDICAL HOLDINGS Reports Q1 Revenue $27.9M, vs. Street Est of $25.8M | MT |
| May. 15 | Transcript : Xtant Medical Holdings, Inc., Q1 2024 Earnings Call, May 15, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 21.06 | 71.72 | 147 | 90.16 | - | - |
| Enterprise Value (EV) 1 | 21.06 | 71.72 | 147 | 90.16 | 90.16 | 90.16 |
| P/E ratio | -2.58 x | -7.33 x | 113 x | -8.66 x | -69.2 x | 34.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.33 x | - | 1.61 x | 0.78 x | 0.69 x | 0.57 x |
| EV / Revenue | 0.33 x | - | 1.61 x | 0.78 x | 0.69 x | 0.57 x |
| EV / EBITDA | 5.44 x | - | 142 x | 19.6 x | 7.51 x | - |
| EV / FCF | - | - | -13.4 x | -25.8 x | - | - |
| FCF Yield | - | - | -7.46% | -3.88% | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13,162 | 108,659 | 130,110 | 130,217 | - | - |
| Reference price 2 | 1.600 | 0.6600 | 1.130 | 0.6924 | 0.6924 | 0.6924 |
| Announcement Date | 3/5/20 | 3/7/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 64.68 | - | 91.3 | 116 | 131.5 | 157 |
| EBITDA 1 | 3.869 | - | 1.038 | 4.6 | 12 | - |
| EBIT 1 | -2.253 | - | -10.16 | -7.2 | 0.5 | 5 |
| Operating Margin | -3.48% | - | -11.13% | -6.21% | 0.38% | 3.18% |
| Earnings before Tax (EBT) 1 | -8.123 | - | -1.037 | -10.7 | -1.25 | 5 |
| Net income 1 | -8.221 | -8.485 | 0.66 | -10.8 | -1.25 | 4 |
| Net margin | -12.71% | - | 0.72% | -9.31% | -0.95% | 2.55% |
| EPS 2 | -0.6200 | -0.0900 | 0.0100 | -0.0800 | -0.0100 | 0.0200 |
| Free Cash Flow 1 | - | - | -10.97 | -3.5 | - | - |
| FCF margin | - | - | -12.02% | -3.02% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/7/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.94 | 20.23 | 25.02 | 28.11 | 27.87 | 28.11 | 29.47 | 32.08 | 29.49 | 31.9 |
| EBITDA 1 | -0.29 | 0.101 | 0.452 | 0.761 | - | 0.3 | 1.799 | 2.42 | 2.281 | 2.624 |
| EBIT 1 | -1.576 | -1.391 | -3.385 | -3.806 | -3.47 | -2.2 | -0.9 | -0.6 | -0.35 | 0.15 |
| Operating Margin | -8.78% | -6.88% | -13.53% | -13.54% | -12.45% | -7.83% | -3.05% | -1.87% | -1.19% | 0.47% |
| Earnings before Tax (EBT) 1 | -2.065 | -2.177 | 6.931 | -3.726 | -4.332 | -3.1 | -1.8 | -1.5 | -0.8 | -0.3 |
| Net income 1 | -2.078 | -2.19 | 9.231 | -4.303 | -4.4 | -3.1 | -1.8 | -1.5 | -0.8 | -0.3 |
| Net margin | -11.58% | -10.82% | 36.9% | -15.31% | -15.79% | -11.03% | -6.11% | -4.68% | -2.71% | -0.94% |
| EPS 2 | -0.0200 | -0.0200 | 0.0700 | -0.0300 | -0.0300 | -0.0200 | -0.0100 | -0.0100 | -0.005000 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/4/23 | 8/1/23 | 11/9/23 | 4/1/24 | 5/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -11 | -3.5 | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 1.46 | 3.5 | 2 | - |
| Capex / Sales | - | - | 1.59% | 3.02% | 1.52% | - |
| Announcement Date | 3/5/20 | 3/7/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6924
USD
Average target price
1.85
USD
Spread / Average Target
+167.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.73% | 90.16M | |
| +11.57% | 127B | |
| -5.05% | 11.32B | |
| +3.22% | 9.04B | |
| +38.90% | 5.56B | |
| -21.83% | 4.72B | |
| +8.74% | 3.45B | |
| -6.82% | 2.86B | |
| -13.32% | 2.04B | |
| -6.99% | 2.07B |
- Stock Market
- Equities
- XTNT Stock
- Financials Xtant Medical Holdings, Inc.
